Technical Program Manager - Product Development

Stifel Nicolaus lowers RxSight (NASDAQ:RXST) price target to $7.00. August 10, 2026 Key points. * Stifel Nicolaus lowered RxSight's price target from $8.00 to $7.00 while maintaining a "hold" rating, implying 11.82% potential upside from the prior close. * Analyst sentiment remains cautious: RxSight has two Buy, seven Hold, and three Sell ratings, resulting in a MarketBeat consensus rating of "Reduce" and an average price target of $8.37. * RxSight reported better-than-expected quarterly results, with an adjusted loss of $0.29 per share versus the $0.33 consensus estimate and revenue of $33.74 million versus $32.55 million expected. * Five stocks to consider instead of RxSight. RxSight (NASDAQ:RXST - Get Free Report) had its price target cut by Stifel Nicolaus from $8.00 to $7.00 in a report released on Monday,Benzinga reports. The brokerage presently has a "hold" rating on the stock. Stifel Nicolaus' price target suggests a potential upside of 11.82% from the stock's previous close. RXST has been the topic of several other reports. UBS Group lifted their target price on RxSight from $5.50 to $6.30 and gave the company a "neutral" rating in a research note on Thursday. Jefferies Financial Group set a $6.50 price target on RxSight in a research note on Tuesday, July 7th. Wells Fargo & Company decreased their price target on RxSight from $11.00 to $9.00 and set an "equal weight" rating for the company in a report on Thursday, May 7th. Weiss Ratings lowered shares of RxSight from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, June 11th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of RxSight in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and an average price target of $8.37. RxSight stock performance. Shares of RXST opened at $6.26 on Monday. RxSight has a fifty-two week low of $4.48 and a fifty-two week high of $13.22. The company has a market capitalization of $260.35 million, a price-to-earnings ratio of -5.54 and a beta of 1.13. The firm has a 50-day simple moving average of $5.31 and a 200-day simple moving average of $6.62. RxSight (NASDAQ:RXST - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.33) by $0.04. The firm had revenue of $33.74 million for the quarter, compared to analyst estimates of $32.55 million. RxSight had a negative return on equity of 17.35% and a negative net margin of 36.80%. Equities research analysts forecast that RxSight will post -1.31 EPS for the current year. Institutional investors weigh in on RxSight. A number of institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. purchased a new position in shares of RxSight during the 2nd quarter worth approximately $28,000. Summit Securities Group LLC purchased a new stake in shares of RxSight in the first quarter valued at approximately $30,000. Larson Financial Group LLC boosted its stake in shares of RxSight by 110.5% in the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company's stock valued at $36,000 after buying an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of RxSight by 440.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company's stock valued at $39,000 after buying an additional 3,063 shares in the last quarter. Finally, CWM LLC grew its holdings in RxSight by 211.1% during the fourth quarter. CWM LLC now owns 3,826 shares of the company's stock worth $40,000 after acquiring an additional 2,596 shares during the period. Hedge funds and other institutional investors own 78.78% of the company's stock. About RxSight. RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non-invasive post-operative adjustments. Using ultraviolet light, surgeons can fine-tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction. Discover more Dividend Screener Tool Stocks & Bonds Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider RxSight, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list. While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge - and the key risks investors should watch as the global AI buildout accelerates.

Plenty of interest in RxSight's Light Adjustable Lens at AUSCRS. Reading Time: 3 mins read RxSight believes Australian cataract surgeons are ready to embrace a technology that has already transformed refractive cataract surgery overseas, using this year's AUSCRS conference to showcase its Light Adjustable Lens (LAL) to the local market. More than 325,000 LALs have now been implanted globally, and with the system now available in Australia, RxSight general manager for Australia and New Zealand Amber Hext said the response from specialists at this week's AUSCRS conference on the Sunshine Coast had exceeded expectations. "There has been a lot of curiosity and a lot of questions about how the LAL can fit into people's practices," she said. "There has also been a healthy level of scepticism, which is great. It's given Insight News the opportunity to showcase the enormous amount of clinical data behind the technology, while also having Dr Baseer Khan on its stand to speak from experience. "Having someone who has performed more than 1,000 implants provides a peer-to-peer discussion that's beyond what we can do." Hext said many delegates had arrived already familiar with the technology from its international success and were eager to understand how they could begin offering it to Australian patients. The LAL is the world's only intraocular lens that can be adjusted after cataract surgery. Following implantation, surgeons use RxSight's Light Delivery Device (LDD) to apply targeted UV light treatments that reshape the lens, allowing postoperative refinement of refractive outcomes before the lens is permanently locked in. Rather than relying solely on preoperative calculations, the system enables surgeons to fine-tune vision after surgery, helping deliver a bespoke refractive result for each patient. Interest at AUSCRS centred on several key topics, including whether the lens delivers extended depth of focus (EDOF)-like performance despite not being classified as an EDOF IOL. "The other big question is who the lens is really for," Hext said. "Many surgeons initially think it's only suited to post-refractive surgery patients, but it's actually appropriate for a much broader cross-section of patients. That's been an important conversation." She said the ability to demonstrate the LDD in person and facilitate discussions with experienced users highlighted the value of exhibiting at conferences. "Marketing and publications all have an important place, but nothing replaces playing on the actual Light Delivery Device, talking to key opinion leaders and having those peer-to-peer conversations," she said. "Human connection always wins." With strong interest already generated, RxSight's next priority is supporting Australia's first wave of LAL adopters while it works towards broader market access. "We've already had surgeons saying, 'I want to get going. What are the next steps?'," Hext said. Early adopters will receive extensive clinical support, with RxSight building its Australian team while drawing on experienced international clinicians to assist with initial cases. "We have an incredible group of international experts who want to come over and support Australian surgeons," Hext said. "We'll be there for those first cases, and if surgeons want to explore the technology, we're ready to have that conversation."

RxSight Tags Aziz Mottiwala as President and CEO, Ron Kurtz, MD, as CMO. Thursday, July 16, 2026 12:27 AM | Aziz Mottiwala (l) and Ron Kurtz, MD. | / | ALISO VIEJO, Calif. - RxSight, Inc. (NASDAQ: RXST), an ophthalmic medical device company focused on providing high-quality customized vision to patients after cataract surgery, has announced a planned leadership transition with the appointment of Aziz Mottiwala as president and chief executive officer, succeeding Ron Kurtz, MD, who will continue to serve the company in the role of chief medical officer. Changes are effective July 20, 2026. In connection with this transition, the company advised that Dr. Kurtz will resign from the board of directors, at which time Mottiwala will be appointed to the board. The company stated it is not updating its previously communicated financial guidance in connection with this announcement. "We are excited to welcome Aziz to RxSight and believe his deep commercial and operational experience in eyecare makes him exceptionally well-suited to lead the company into its next chapter of value creation," said Andy Corley, chairman of the RxSight board of directors. "On behalf of the board, I want to express our sincere appreciation to Ron for his vision and leadership in establishing adjustability in the ophthalmic marketplace, and for his continued commitment to advancing our technology and clinical value as chief medical officer. Ron's track record of product development is well known throughout the ophthalmic community, and we look forward to his continued leadership as we expand adjustability into broader market segments." In making the announcement, RxSight lauded Mottiwala, saying he brings extensive commercial leadership experience across eyecare, with a proven track record of building and scaling high-performing commercial organizations. He most recently served as chief commercial officer at Tarsus Pharmaceuticals, which had announced his departure earlier this week, and previously held the same role at Opiant Pharmaceuticals. Before that, Mottiwala spent more than a decade at Allergan, where he held senior leadership positions across the company's eyecare franchise and broader commercial organization, the company noted. He holds a bachelor's degree in biochemistry from the University of California, San Diego, and a master's degree in business administration from the University of Southern California. "I am excited and honored to join RxSight at such a critical time for the company," said Mottiwala. "RxSight has created a unique and differentiated platform with significant opportunity ahead. Adjustability has brought a new level of accuracy and customization to modern cataract surgery that is still in the early stages of market adoption." "RxSight is well positioned to further its mission of transforming cataract surgery through adjustability, making this the right time for me to focus on areas where I can have the greatest impact" said Dr. Kurtz. "I look forward to working closely with Aziz, the RxSight team, and our clinical partners to continue bringing life-changing innovations and personalized vision to patients." These leadership changes follow a news announcement from RxSight on July 6 advising of the company's non-exclusive collaboration with Alcon to jointly develop adjustable, presbyopia-correcting intraocular lenses. As part of the agreement, RxSight will receive a $60 million upfront payment to begin development and could receive up to an additional $140 million in payments as development and regulatory milestones are met, the announcement stated at the time. On July 7, RxSight reported select preliminary financial results for the second quarter of 2026, which demonstrated expected total company revenue of approximately $32 million to $34 million. This includes $5 million to $7 million in revenue recognized from the RxSight-Alcon collaboration, with the specific amount expected to be reported in August with the company's financial results for the second quarter of 2026.